PrimeC PARADIGM trial drops U.S. sites, adds Canada, Germany
The Phase 2b trial testing PrimeC in people with amyotrophic lateral sclerosis (ALS) will no longer enroll patients in…
Articles by Lindsey Shapiro, PhD
Phase 1/2 trial of imaging agent for inflammation enrolls 1st ALS patient
A Phase 1/2 clinical trial testing the investigational imaging agent 18F-OP-801 in healthy volunteers and people with amyotrophic lateral sclerosis…
Herbal Skin Patch as Add-on Therapy Slows ALS Progression, Trial Finds
Adding a skin patch containing a Chinese herb mixture called Ji Wu Li (JWL) to standard medications significantly slowed disease…
Brain Implant May Someday Help ALS Patients Communicate
Researchers have developed a brain-machine interface (BMI) that could someday facilitate communication for people who have lost their ability to…
Veterans Call for FDA Committee Meeting on NurOwn’s Benefits
Veterans with amyotrophic lateral sclerosis (ALS) are calling for the U.S. Food and Drug Administration (FDA) to hold a…
Trial of BIIB105 Enrolling Patients With or Without ATXN2 Mutations
A Phase 1/2 clinical trial is investigating the long-term safety and tolerability of BIIB105, Biogen‘s investigational treatment targeting…
NurOwn Continues to Show Benefit in Rapidly Advancing ALS
The investigational cell-based therapy NurOwn may slow disease progression in people with amyotrophic lateral sclerosis (ALS) who…
Tofersen’s Clinical Benefits for ALS Linked to NfL Levels: Trial Data
Early declines in neurofilament light chain (NfL), a biomarker of nerve cell damage, after treatment with tofersen may predict…
Changes to ALS Registry for US May Better Capture Disease Prevalence
Proposed updates to the National ALS Registry’s case-identification algorithm and classifications may help provide a better estimate of the…
Phase 2 Trial Will Test Cortisol Modulator Dazucorilant in ALS
Dazucorilant, Corcept Therapeutics‘ investigational cortisol modulator for people with amyotrophic lateral sclerosis (ALS), is being evaluated in a…